Literature DB >> 2208153

Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption.

A W Norman1, J Y Zhou, H L Henry, M R Uskokovic, H P Koeffler.   

Abstract

The hormonally active form of vitamin D, 1 alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3], is an efficient stimulator of intestinal calcium absorption (ICA) and bone calcium mobilization (BCM) in humans and experimental animals and, as well, has been shown to be effective in inducing differentiation and inhibiting proliferation of leukemia cells. Thus, it has been proposed that analogues of 1,25(OH)2D3 could be synthesized which might allow for separation of biological functions, i.e., promote a differentiation of leukemia cells without a significant stimulation of ICA or BCM, both biological effects which can cause hypercalcemia in humans. Here we report the results of an evaluation of four analogues of the previously studied (Zhou et al., Blood, 74:82-92, 1989) 1 alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 [1,25(OH)2-16-ene-23-yne-D3]; these analogues allowed evaluation of the consequences of (a) the presence or absence of six deuterium atoms on carbons 26 and 27 of the side chain and (b) the deletion or substitution by a fluorine atom of the 1 alpha-hydroxyl group on the A-ring. The 1,25(OH)2-16-ene-23-yne-D3 analogue was found to be 7-fold more potent than the parent 1,25(OH)2D3 with respect to (a) inhibition of clonal proliferation of HL-60 cells as well as (b) induction of differentiation of HL-60 promyelocytes. Variants of this analogue which possessed the six deuterium atoms on carbons 26 and 27 were slightly less active than the 1,25(OH)2-16-ene-yne-D3. However, replacement of the 1 alpha-hydroxyl group by a 1-fluoro group, or the absence of the 1-hydroxyl group, resulted in analogues that were somewhat less effective than the parent 1,25(OH)2D3 in achieving these biological responses but more potent as inhibitors of the renal mitochondrial 25-OH-D3-1 alpha-hydroxylase, the site of endogenous production of 1,25(OH)2D3. ICA and BCM were assessed in vivo in vitamin D-deficient chickens, and each of the analogues was markedly less potent than the standard 1,25(OH)2D3. The analogue 1,25(OH)2-16-ene-23-yne-D3 had 2% of the ICA and 3% of the BCM activity of the parent 1,25(OH)2D3. Absence of the 1 alpha-hydroxyl group or substitution of the 1-fluoro group for the 1-hydroxyl group significantly diminished both the ICA and BCM activity in comparison to 1,25(OH)2-16-ene-23-yne-D3. Receptor binding studies indicated that 1,25(OH)2-16-ene-23-yne-D3 competed about 75% as effectively as 1,25(OH)2D3 for 1,25(OH)2D3 receptors present in both chick intestinal cells and HL-60 cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208153

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.

Authors:  Sylvia Christakos; Puneet Dhawan; Annemieke Verstuyf; Lieve Verlinden; Geert Carmeliet
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  Interactions of 1,25(OH)(2)D (3) and retinoic acid in the regulation of IEC-6 cell alkaline phosphatase activity.

Authors:  Y J Jeng; M L Thomas
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

3.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

4.  Effects of analogs of 1,25(OH)2 vitamin D3 on the proliferation and differentiation of the human chronic myelogenous leukemia cell line, RWLeu-4.

Authors:  J W Clark; M R Posner; J M Marsella; A Santos; M Uskokovic; C Eil; S R Lasky
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Novel Gemini vitamin D(3) analogs have potent antitumor activity.

Authors:  Tsuyako Saito; Ryoko Okamoto; Talin Haritunians; James O'Kelly; Milan Uskokovic; Hubert Maehr; Stanislaw Marczak; Pawel Jankowski; Riem Badr; H Phillip Koeffler
Journal:  J Steroid Biochem Mol Biol       Date:  2008-09-30       Impact factor: 4.292

6.  Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway.

Authors:  Jing Zhang; Gary H Posner; Michael Danilenko; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-16       Impact factor: 4.292

7.  Vitamin D receptors in breast cancer cells.

Authors:  R R Buras; L M Schumaker; F Davoodi; R V Brenner; M Shabahang; R J Nauta; S R Evans
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid.

Authors:  M J Campbell; S Park; M R Uskokovic; M I Dawson; L Jong; H P Koeffler
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

9.  The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma.

Authors:  T Hickish; D Cunningham; K Colston; B C Millar; J Sandle; A G Mackay; M Soukop; J Sloane
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

10.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

Authors:  T Gulliford; J English; K W Colston; P Menday; S Moller; R C Coombes
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.